Pharmaceutical company Bayer announced Wednesday that fresh analysis of clinical trial data demonstrates their investigational blood-thinning medication asundexian successfully lowered both the occurrence and intensity of repeat ischemic strokes.
Results from the phase III clinical study revealed that patients taking the experimental drug experienced ischemic strokes at a rate of 6.2%, while those receiving a placebo had strokes occur 8.4% of the time. The trial focused on individuals who had previously experienced non-cardioembolic ischemic strokes or high-risk transient ischemic attacks.
The findings represent a potential breakthrough for stroke prevention therapy, offering hope for patients at elevated risk of experiencing additional cerebrovascular events.
